• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型 C-11 标记苯并-1,4-二恶烷 PET 放射性示踪剂用于脑 α2C 肾上腺素能受体的临床前评估。

Preclinical evaluation of new C-11 labeled benzo-1,4-dioxane PET radiotracers for brain α2C adrenergic receptors.

机构信息

University of Missouri Research Reactor, University of Missouri, Columbia, MO, 65211, USA.

Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, MD, 20892-1013, USA.

出版信息

Eur J Med Chem. 2022 Dec 5;243:114764. doi: 10.1016/j.ejmech.2022.114764. Epub 2022 Sep 17.

DOI:10.1016/j.ejmech.2022.114764
PMID:36272201
Abstract

As one of the nine subtypes of adrenergic receptors (ARs) in the brain, α2C-ARs play essential roles in emotion and memory, and are implicated in neuropsychiatric disorders, including depression, Alzheimer's disease, substance use disorder, and schizophrenia. A recently developed α2C-AR specific positron emission tomography (PET) radiotracer, [C]ORM-13070, showed promise for imaging α2C-ARs in the brain. Herein, we prepared highly potent C-11 labeled benzo-1,4-dioxane derivatives and compared them with [C]ORM-13070, aiming to improve the specific binding signal, as evaluated by in vivo rodent brain PET imaging.© 2022 Elsevier Inc. All rights reserved.

摘要

作为大脑中九种肾上腺素能受体 (AR) 亚型之一,α2C-AR 在情绪和记忆中发挥着重要作用,并与神经精神疾病有关,包括抑郁症、阿尔茨海默病、物质使用障碍和精神分裂症。最近开发的一种 α2C-AR 特异性正电子发射断层扫描 (PET) 放射性示踪剂 [C]ORM-13070,为脑内 α2C-AR 成像提供了希望。在此,我们制备了高活性的 C-11 标记苯并-1,4-二恶烷衍生物,并将其与 [C]ORM-13070 进行了比较,旨在通过体内啮齿动物脑 PET 成像来提高特异性结合信号。© 2022 年 Elsevier Inc. 保留所有权利。

相似文献

1
Preclinical evaluation of new C-11 labeled benzo-1,4-dioxane PET radiotracers for brain α2C adrenergic receptors.新型 C-11 标记苯并-1,4-二恶烷 PET 放射性示踪剂用于脑 α2C 肾上腺素能受体的临床前评估。
Eur J Med Chem. 2022 Dec 5;243:114764. doi: 10.1016/j.ejmech.2022.114764. Epub 2022 Sep 17.
2
A PET Tracer for Brain α2C Adrenoceptors, (11)C-ORM-13070: Radiosynthesis and Preclinical Evaluation in Rats and Knockout Mice.一种用于脑 α2C 肾上腺素能受体的 PET 示踪剂,(11)C-ORM-13070:在大鼠和基因敲除小鼠中的放射合成和临床前评估。
J Nucl Med. 2014 Jul;55(7):1171-7. doi: 10.2967/jnumed.113.135574. Epub 2014 May 5.
3
Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain.[(11)C]ORM-13070作为人脑α2c-肾上腺素能受体PET示踪剂的验证
Synapse. 2015 Mar;69(3):172-81. doi: 10.1002/syn.21798. Epub 2015 Jan 8.
4
Preclinical and evaluation of [C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates.使用正电子发射断层扫描(PET)成像在非人类灵长类动物中对[C]ORM-13070作为用于α-2C肾上腺素能受体占据的PET配体进行临床前研究和评估。
J Cereb Blood Flow Metab. 2025 Apr;45(4):677-689. doi: 10.1177/0271678X241291949. Epub 2024 Oct 31.
5
Amphetamine decreases α2C-adrenoceptor binding of [11C]ORM-13070: a PET study in the primate brain.苯丙胺降低[11C]ORM-13070与α2C-肾上腺素能受体的结合:灵长类动物脑PET研究
Int J Neuropsychopharmacol. 2014 Dec 13;18(3):pyu081. doi: 10.1093/ijnp/pyu081.
6
¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men.¹¹C-ORM-13070,一种新型用于脑 α₂C-肾上腺素能受体的 PET 配体:在健康男性中的放射性代谢、血浆药代动力学、全身分布和辐射剂量学。
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1947-56. doi: 10.1007/s00259-014-2782-y. Epub 2014 May 17.
7
Pharmacological characterisation of a structurally novel α2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models.新型 α2C-肾上腺素能受体拮抗剂 ORM-10921 的药理学特性及其在神经精神疾病模型中的作用。
Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):239-49. doi: 10.1111/bcpt.12090. Epub 2013 Jun 20.
8
Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain.(11)C-ORM-13070 在人体大脑中 α2C-肾上腺素能受体的 PET 成像中的测试 - 重测可靠性。
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):120-7. doi: 10.1007/s00259-014-2899-z. Epub 2014 Sep 9.
9
In vivo evaluation of limiting brain penetration of probes for α(2C)-adrenoceptor using small-animal positron emission tomography.使用小动物正电子发射断层扫描技术评价用于 α(2C)-肾上腺素能受体的探针的脑穿透极限。
ACS Chem Neurosci. 2010 Jul 21;1(7):520-8. doi: 10.1021/cn1000364. Epub 2010 Jun 2.
10
Application of the PET ligand [C]ORM-13070 to examine receptor occupancy by the α-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain.PET配体[C]ORM-13070用于检测α-肾上腺素能受体拮抗剂ORM-12741的受体占有率:大鼠和人脑中靶点结合的转化验证
EJNMMI Res. 2020 Dec 9;10(1):152. doi: 10.1186/s13550-020-00741-y.

引用本文的文献

1
Identification of (L.) Merr as a Novel Potential Therapeutic Agent Against COVID-19 and Pharyngitis.鉴定(L.)Merr为一种针对新型冠状病毒肺炎和咽炎的新型潜在治疗剂。
Molecules. 2025 Feb 25;30(5):1055. doi: 10.3390/molecules30051055.
2
Therapeutic Potential of Dexmedetomidine in Neuropsychiatric Disorders: From the Bench to the Clinic.右美托咪定在神经精神疾病中的治疗潜力:从实验室到临床
Curr Neuropharmacol. 2025;23(8):929-942. doi: 10.2174/011570159X349530241123140415.
3
Development and Optimization of C-Labeled Radiotracers: A Review of the Modern Quality Control Design Process.

本文引用的文献

1
Application of the PET ligand [C]ORM-13070 to examine receptor occupancy by the α-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain.PET配体[C]ORM-13070用于检测α-肾上腺素能受体拮抗剂ORM-12741的受体占有率:大鼠和人脑中靶点结合的转化验证
EJNMMI Res. 2020 Dec 9;10(1):152. doi: 10.1186/s13550-020-00741-y.
2
PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives.用于中枢神经系统肾上腺素能受体的正电子发射断层扫描放射性示踪剂:进展与展望。
Molecules. 2020 Sep 3;25(17):4017. doi: 10.3390/molecules25174017.
3
Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation.
碳标记放射性示踪剂的研发与优化:现代质量控制设计流程综述
ACS Pharmacol Transl Sci. 2023 Oct 11;6(11):1616-1631. doi: 10.1021/acsptsci.3c00200. eCollection 2023 Nov 10.
死亡受体 5 通过表皮生长因子受体的转激活促进心肌细胞肥大。
J Mol Cell Cardiol. 2019 Nov;136:1-14. doi: 10.1016/j.yjmcc.2019.08.011. Epub 2019 Aug 29.
4
Noradrenergic targets for the treatment of alcohol use disorder.去甲肾上腺素能靶点治疗酒精使用障碍。
Psychopharmacology (Berl). 2018 Jun;235(6):1625-1634. doi: 10.1007/s00213-018-4843-6. Epub 2018 Feb 20.
5
Therapeutic Potential of Selectively Targeting the α-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.选择性靶向α-肾上腺素能受体在认知、抑郁和精神分裂症中的治疗潜力——新进展与未来展望
Front Psychiatry. 2017 Aug 14;8:144. doi: 10.3389/fpsyt.2017.00144. eCollection 2017.
6
The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol.α2C-肾上腺素受体拮抗剂,ORM-10921,在社会隔离饲养的大鼠中具有抗精神病样作用,并增强了对氟哌啶醇的反应。
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:108-16. doi: 10.1016/j.pnpbp.2016.07.002. Epub 2016 Jul 2.
7
Mapping α2 adrenoceptors of the human brain with 11C-yohimbine.用¹¹C-育亨宾对人脑α2肾上腺素能受体进行定位
J Nucl Med. 2015 Mar;56(3):392-8. doi: 10.2967/jnumed.114.145565. Epub 2015 Jan 29.
8
Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain.[(11)C]ORM-13070作为人脑α2c-肾上腺素能受体PET示踪剂的验证
Synapse. 2015 Mar;69(3):172-81. doi: 10.1002/syn.21798. Epub 2015 Jan 8.
9
¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men.¹¹C-ORM-13070,一种新型用于脑 α₂C-肾上腺素能受体的 PET 配体:在健康男性中的放射性代谢、血浆药代动力学、全身分布和辐射剂量学。
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1947-56. doi: 10.1007/s00259-014-2782-y. Epub 2014 May 17.
10
A PET Tracer for Brain α2C Adrenoceptors, (11)C-ORM-13070: Radiosynthesis and Preclinical Evaluation in Rats and Knockout Mice.一种用于脑 α2C 肾上腺素能受体的 PET 示踪剂,(11)C-ORM-13070:在大鼠和基因敲除小鼠中的放射合成和临床前评估。
J Nucl Med. 2014 Jul;55(7):1171-7. doi: 10.2967/jnumed.113.135574. Epub 2014 May 5.